A Second Leg for CorMedix

Rezzayo Hits Across All Three Pathogens, Setting Up a 2H26 Filing and 2027 Launch

This will be a "best ideas only" bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

CorMedix reported positive topline data on April 27 from the Phase III ReSPECT trial of Rezzayo (rezafungin) for prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant patients. In the 602-patient comparison against standard of care (investigator’s choice of posaconazole, fluconazole, or TMP/SMX), Rezzayo met its primary non-inferiority endpoint with a fungal-free survival rate of 61 percent at day 90, against 59 percent for the active comparators. The trial was not powered for superiority, and the numerical delta sits firmly inside non-inferiority territory and should not be read as a superiority signal.